Pharmaceutical

EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma

BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.

Jul 13, 2025 - 06:00
EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma
BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.
Read the original article

Tags:

Previous Article

Future Foods: Past Insights Driving SDG-2 Progress

Next Article

FDA publishes more than 200 archived CRLs for transparency

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare Advantage insurers face slight proposed cut to 2025 payments

STAT+: Medicare Advantage insurers face slight proposed...

Feb 1, 2024

Key opinion leaders on unmet needs in amyotrophic lateral sclerosis

Key opinion leaders on unmet needs in amyotrophic later...

Jun 2, 2024

STAT+: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm

STAT+: FDA advisers vote overwhelmingly against ALS tre...

Sep 28, 2023